BioSpace News Archive

BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference.

The Life Science division of Meridian Bioscience, Inc. has announced the launch of a comprehensive menu of glycerol-free NGS enzymes for use in all steps of a Next Generation Sequencing (“NGS”) workflow.

Neuboron Medical Group (Neuboron) is pleased to announce significant progress in the commercialization of its comprehensive Boron Neutron Capture Therapy (BNCT) solution, marking a new era in the treatment of refractory tumors.

IBD or Inflammatory Bowel Disease, traditionally more prevalent in developed nations, is increasingly observed in developing regions like China .

AlzeCure Pharma AB announced that Professor Jan Lundberg invests in the company and is proposed as a new member of the company’s board of directors.

BioArctic AB’s commitment to its Sustainable Innovation approach - combining scientific progress with responsible business practices and a dedication to environmental, social, and corporate governance principles - has earned the company a place on the new Nasdaq OMX Sweden Small Cap 30 ESG Responsibility Index launched.

ViGeneron GmbH announced that the first patient has been dosed in its Phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa caused by mutations in the CNGA1 gene.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce record sales of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve.

Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced the appointment of Dr. Snehal Shah, executive leader with over two decades of research & development and regulatory experience, to the role of President of R&D.